Who makes AK129 IV infusion?

AK129 IV infusion is developed by Akeso.

What development phase is AK129 IV infusion in?

AK129 IV infusion is in Phase 1.

Last reviewed 2026-04-23 · How we verify

AK129 IV infusion

Akeso · Phase 1 active Small molecule

At a glance

Generic name	AK129 IV infusion
Sponsor	Akeso
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

AK129 Combination Therapy for Advanced Solid Tumors (PHASE1, PHASE2)
A Study of AK129 in Patients With Advanced Malignant Tumors (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

AK129 IV infusion CI brief — competitive landscape report
AK129 IV infusion updates RSS · CI watch RSS
Akeso portfolio CI